Authors
Yingzi Chang, Jacques Robidoux
Publication date
2017/4/1
Source
Current opinion in pharmacology
Volume
33
Pages
47-55
Publisher
Elsevier
Description
Highlights
- Statins reduce the risk of ASCVD by decreasing the biosynthesis of cholesterol.
- PCSK9 antibodies are used as an add-on therapy to further reduce cholesterol levels in patients receiving optimized statin therapy.
- Apo B-100 and MTP inhibitors are used to treat patients with HoFH.
Association of hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) is well established. Reducing low-density lipoprotein-cholesterol (LDL-C) and raising high-density lipoprotein-cholesterol (HDL-C) have been the therapeutic targets to reduce the risk of ASCVD. Cholesterol-lowering medications have been used to provide both primary and secondary prevention of ASCVD for many years by reducing the absorption and reabsorption, promoting excretion, or decreasing the synthesis of cholesterol. Within the past five years, several new classes of cholesterol-lowering drugs have been tested and approved for …
Scholar articles
Y Chang, J Robidoux - Current opinion in pharmacology, 2017